We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

77 hedge funds and large institutions have $135M invested in AVEO Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,171% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $291K

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

38% more funds holding

Funds holding: 56 → 77 (+21)

33% more capital invested

Capital invested by funds: $101M → $135M (+$33.8M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

Holders
77
Holders Change
+21
Holders Change %
+37.5%
% of All Funds
1.33%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
17
Reduced
17
Closed
6
Calls
$3.7M
Puts
$291K
Net Calls
+$3.41M
Net Calls Change
+$641K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$5.69M
2
GC
Globeflex Capital
California
+$2.83M
3
EGI
EAM Global Investors
California
+$1.63M
4
EI
EAM Investors
California
+$1.49M
5
Invesco
Invesco
Georgia
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$5.09M
2
Millennium Management
Millennium Management
New York
-$3.78M
3
ACM
AIGH Capital Management
Maryland
-$1.6M
4
SSA
Schonfeld Strategic Advisors
New York
-$1.54M
5
WVP
Worth Venture Partners
New Jersey
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
26
Cubist Systematic Strategies
Connecticut
$524K +$489K +63,702 New
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$485K +$452K +58,900 New
WMSA
28
Weiss Multi-Strategy Advisers
New York
$478K -$22.1K -2,876 -5%
Goldman Sachs
29
Goldman Sachs
New York
$476K +$283K +36,797 +175%
Bank of America
30
Bank of America
North Carolina
$449K +$42.5K +5,537 +11%
BCM
31
Bridgeway Capital Management
Texas
$436K – – –
Northern Trust
32
Northern Trust
Illinois
$415K -$13.1K -1,705 -3%
Two Sigma Investments
33
Two Sigma Investments
New York
$387K +$361K +47,002 New
AA
34
Ancora Advisors
Ohio
$380K – – –
Acadian Asset Management
35
Acadian Asset Management
Massachusetts
$352K +$330K +42,980 New
EWM
36
Evercore Wealth Management
New York
$344K – – –
Citadel Advisors
37
Citadel Advisors
Florida
$336K +$313K +40,802 New
OQS
38
Occudo Quantitative Strategies
Florida
$334K +$312K +40,568 New
JF
39
Jump Financial
Illinois
$263K +$11K +1,432 +5%
GCP
40
GSA Capital Partners
United Kingdom
$249K -$24.3K -3,163 -9%
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$244K +$83.4K +10,859 +58%
TI
42
Trexquant Investment
Connecticut
$220K +$206K +26,770 New
Dimensional Fund Advisors
43
Dimensional Fund Advisors
Texas
$191K -$13.8K -1,800 -7%
Connor, Clark & Lunn Investment Management (CC&L)
44
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$177K +$166K +21,563 New
GC
45
Grimes & Company
Massachusetts
$159K – – –
Bank of New York Mellon
46
Bank of New York Mellon
New York
$133K +$124K +16,151 New
Two Sigma Advisers
47
Two Sigma Advisers
New York
$132K +$123K +16,000 New
B
48
Bailard
California
$125K +$117K +15,200 New
ECM
49
ExodusPoint Capital Management
New York
$120K +$112K +14,548 New
SFI
50
Susquehanna Fundamental Investments
Pennsylvania
$108K +$101K +13,130 New
1
2
3 4

AVEO Hedge Fund Activity: Q3 2022 in Review

77 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2022, worth a combined $135M — up 33% from $101M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVEO positions and 6 closed out — a net gain of 21 holders — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $5.69M. The largest seller was J. Goldman & Co, cutting an estimated $5.09M.

  • 77 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2022, up from 56 in Q2 2022.
  • Funds reported $135M of AVEO Pharmaceuticals, Inc. stock for Q3 2022, up 33% quarter-over-quarter.
  • 27 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2022 and 6 closed out, a net change of +21 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $5.69M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q3 2022 was J. Goldman & Co, an estimated $5.09M sold.

Based on aggregated 13F filings for Q3 2022.